TY - JOUR T1 - Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma JF - In Vivo JO - In Vivo SP - 2967 LP - 2972 DO - 10.21873/invivo.12127 VL - 34 IS - 5 AU - HIROKI SATO AU - CHIHIRO FUSHIMI AU - TAKURO OKADA AU - TAKASHI MATSUKI AU - TAKAHITO KONDO AU - GO OMURA AU - KOUKI MIURA AU - TAKU YAMASHITA AU - ISAKU OKAMOTO AU - KIYOAKI TSUKAHARA Y1 - 2020/09/01 UR - http://iv.iiarjournals.org/content/34/5/2967.abstract N2 - Background/Aim: Nivolumab, an anti-PD-1 inhibitor, has demonstrated efficacy in patients with several types of recurrent and metastatic (R/M) squamous cell carcinoma of the head and neck. We evaluated patients with R/M-NPC receiving nivolumab. Patients and Methods: Twelve patients with R/M-NPC were enrolled at 4 institutions. The primary endpoint was overall survival, and secondary endpoints were i) progression-free survival (PFS), ii) overall response rate (ORR), iii) disease control rate (DCR), and iv) treatment-related toxicity. Results: The 1-year survival rate was 75.8%, the median PFS was 2.8 months, and the 1-year PFS rate was 33.3%. The best therapeutic response was complete response in 2, stable disease in 3 and progressive disease in 7 patients. The ORR of all patients was 16.7% and the DCR was 41.7%. Conclusion: Nivolumab is a useful and relatively safe second-line systemic therapy in patients with R/M-NPC, and even patients who do not respond to nivolumab may survive for a long time. ER -